Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:50:19.340Z.
Calculation as of: 2026-10-06T15:50:19.340Z.
Quote observation: 2026-10-06T15:50:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6f641a2bf51a69a6e8cdb13afe7e76557325a462d28890c99da58f5868e3b8e6
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | $1.89B | N/A | N/A | N/A | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | N/A | N/A | N/A | N/A |
| Azenta, Inc. (AZTA)vs › | $1.88B | N/A | 2.28 | 2.28 | 2.28 |
| Novavax, Inc. (NVAX)vs › | $1.88B | N/A | N/A | N/A | N/A |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.86B | N/A | N/A | N/A | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.84B | N/A | 0.91 | 8.33 | 8.33 |
| Novocure Ltd (NVCR)vs › | $1.84B | N/A | N/A | N/A | N/A |
| Absci Corporation (ABSI)vs › | $1.84B | N/A | N/A | N/A | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.95B | N/A | 0.02 | 0.02 | 0.02 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.94B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
